These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 33462417)

  • 1. ACEi reduces hypertension-induced hyperinflammation in COVID-19.
    Lim GB
    Nat Rev Cardiol; 2021 Apr; 18(4):231. PubMed ID: 33462417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
    Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
    BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study).
    Mustafic H; Fayssoil A; Josseran L; Ouadahi M; Grimaldi-Bensouda L; Dubourg O; Annane D; Mansencal N
    Am J Cardiol; 2021 May; 147():58-60. PubMed ID: 33617818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.
    Melissa Hallow K; Dave I
    Clin Pharmacol Ther; 2021 Apr; 109(4):1092-1103. PubMed ID: 33506503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.
    Yuan Y; Liu D; Zeng S; Wang S; Xu S; Wang Y; Yu R; Gao Y; Li H; Feng X; Zhou N; Zhao C; Gao Q
    J Infect; 2020 Nov; 81(5):816-846. PubMed ID: 32800800
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19 and ACEI/ARB: Not Associated?
    Hajra A; Bandyopadhyay D
    Am J Hypertens; 2020 Aug; 33(8):788. PubMed ID: 32415832
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 and Comorbid Hypertension: Is ACE2 the Culprit?
    Zhang T; Zhong S; Cao W
    Prehosp Disaster Med; 2020 Dec; 35(6):700-701. PubMed ID: 32838828
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
    Huang W; Li T; Ling Y; Qian ZP; Zhang YY; Huang D; Xu SB; Liu XH; Xia L; Yang Y; Lu SH; Lu HZ
    Zhonghua Nei Ke Za Zhi; 2020 Sep; 59(9):689-694. PubMed ID: 32838499
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19.
    Rouette J; Suissa K; Azoulay L
    Epidemiology; 2020 Nov; 31(6):e52-e53. PubMed ID: 33555810
    [No Abstract]   [Full Text] [Related]  

  • 12. Is there a difference in the effect between the ACEI and ARB on COVID-19?
    Chen J; Mei K; Deng C
    Clin Cardiol; 2021 Jan; 44(1):5-6. PubMed ID: 33205837
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
    Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
    PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.
    Kow CS; Hasan SS
    Expert Rev Cardiovasc Ther; 2021 Jan; 19(1):99-100. PubMed ID: 33112190
    [No Abstract]   [Full Text] [Related]  

  • 15. ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?
    Murthy VL; Koupenova M; Shah RV
    Circ Res; 2020 Jun; 126(12):1682-1684. PubMed ID: 32302248
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to the letter to the editor entitled 'Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic'.
    Bottino LG; Fuchs FD
    Expert Rev Cardiovasc Ther; 2021 Feb; 19(2):189-190. PubMed ID: 33297777
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.
    Oussalah A; Gleye S; Clerc Urmes I; Laugel E; Callet J; Barbé F; Orlowski S; Malaplate C; Aimone-Gastin I; Caillierez BM; Merten M; Jeannesson E; Kormann R; Olivier JL; Rodriguez-Guéant RM; Namour F; Bevilacqua S; Losser MR; Levy B; Kimmoun A; Gibot S; Thilly N; Frimat L; Schvoerer E; Guéant JL
    Clin Infect Dis; 2020 Dec; 71(9):2447-2456. PubMed ID: 32623470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.
    Volpe M; Patrono C
    Eur Heart J; 2021 Mar; 42(11):1061-1062. PubMed ID: 33659979
    [No Abstract]   [Full Text] [Related]  

  • 19. The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis.
    Xu J; Teng Y; Shang L; Gu X; Fan G; Chen Y; Tian R; Zhang S; Cao B
    Clin Infect Dis; 2021 Jun; 72(11):e901-e913. PubMed ID: 33079200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors.
    Golpe R; Pérez-de-Llano LA; Dacal D; Guerrero-Sande H; Pombo-Vide B; Ventura-Valcárcel P;
    Med Clin (Barc); 2020 Dec; 155(11):488-490. PubMed ID: 32651067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.